Search

Dissolvable cleaning products, such as tablets, pods, or powders, are marketed as environmentally friendly alternatives to traditional spray cleaners packaged in plastic bottles. These products eliminate the need for water, reducing packaging and transportation waste. However, in tests conducted by CHOICE, dissolvable cleaning products did not perform as well as traditional sprays, scoring lower in cleaning power. While they may be worth considering for their environmental benefits, consumers should weigh the pros and cons and consider other options, such as eco sprays in recycled plastic bottles or making their own cleaning products. [Extracted from the article]

A patent application titled "R-Ketamine Salts And Methods Of Use Thereof" was published online by inventors JUMAA, Mouhannad and KELLY, Terence Alfred. The application focuses on new salts and salt forms of R-ketamine for pharmaceutical composition development. Various crystalline polymorphic forms of R-ketamine salts, including saccharin, fumarate, succinate, sulfate, and D-tartrate, are described in the patent application. The application aims to optimize the manufacturing of R-ketamine for therapeutic use in treating neurological conditions. [Extracted from the article]

A recent study from Jiangnan University in Wuxi, China, explores the use of spray-congealing to encapsulate fumaric acid in solid lipid microparticles for the baking industry. The research investigates the impact of different lipid carriers and surfactants on the release of fumaric acid, aiming to optimize its functionality while preserving the quality of baked goods. The findings suggest that customizing release kinetics through surfactant-enhanced solid lipid microparticles could lead to a controlled-release system tailored to specific baking applications. This study may contribute to advancements in food research and development, particularly in the baking industry. [Extracted from the article]

A recent study conducted by Nanjing University of Chinese Medicine examined the effects of tenofovir alafenamide fumarate (TAF) treatment on lipid profiles in patients with chronic hepatitis B (CHB). The study included 430 patients with CHB, with 158 patients receiving TAF treatment and 272 patients receiving tenofovir disoproxil fumarate (TDF) treatment. The results showed that TAF treatment was associated with dyslipidemia, with significantly elevated triglyceride (TG) and total cholesterol (TC) levels. The study suggests that close monitoring of lipid profiles is necessary for CHB patients receiving TAF treatment. [Extracted from the article]

A recent study conducted by Leipzig University Medical Center in Germany has found that tenofovir alafenamide (TAF) is a safe and effective treatment for chronic hepatitis B (CHB) patients, even in those with decreased renal function. TAF is a prodrug of tenofovir that has shown a favorable renal safety profile while effectively suppressing HBV DNA. The study included 50 patients with CHB who received TAF treatment for an average of 18 months. The results showed a significant decrease in HBV DNA levels and stable renal function throughout the observation period. Mild adverse events were reported by 28% of the patients. This research provides valuable insights into the real-world use of TAF in European patients with CHB. [Extracted from the article]

A recent study conducted by researchers at the University of the Basque Country (UPV) in Spain has found that dimethyl fumarate (DMF) shows potential as a treatment for neonatal encephalopathy, a condition caused by neonatal hypoxia-ischemia that can lead to infant death and disability. The study used a modified Rice-Vannucci model to induce severe hypoxic-ischemic brain damage in neonatal rats and found that DMF reduced brain tissue loss, improved neuropathological scores, preserved myelin tracts, and reduced astroglial and microglial activation. While further research is needed, this study suggests that DMF could be a promising treatment for neonatal encephalopathy. [Extracted from the article]

A study conducted by researchers at Universidad Anahuac Mexico aimed to analyze the effect of different drying treatments on the metabolome of cacao pod husk (CPH). The researchers used untargeted proton nuclear magnetic resonance (1H NMR) and chemometric analysis to obtain the fingerprint of CPH and identify the compounds present. They found that freeze drying preserved the metabolites better than microwave drying or hot air drying, and that freeze drying and microwave drying had similar compositions after drying. This research provides valuable information on the composition of CPH and how it is affected by the dehydration process. [Extracted from the article]

This article discusses a clinical trial, NCT06602622, that is studying the effects of changing HIV treatment on body weight. The trial will include patients who have developed metabolic syndrome after starting HIV treatment or antiretroviral therapy and have gained at least 10% of their body weight. Participants will be randomly assigned to either continue their current treatment or switch to another treatment. The study will evaluate changes in body weight, BMI, lipid profile, body composition, cardiovascular risk, kidney function, and neuropsychiatric disorders over a period of 48 weeks. The document outlines the procedures and methods for the trial, including medical interviews, informed consent, and various measurements and tests. The goal is to determine the impact of switching HIV medication regimens on weight and BMI. The trial is currently recruiting participants and is expected to be completed by November 2025. [Extracted from the article]

Researchers at the University Clinic of Dentistry in Vienna, Austria have conducted a study on the use of dimethyl fumarate (DMF) in reducing chemokine expression in oral cells. DMF, originally proposed as a treatment for multiple sclerosis, has anti-inflammatory effects that can effectively control periodontitis when applied with a hydrogel delivery system. The researchers found that DMF effectively reduced the expression of certain chemokines and lowered the phosphorylation of certain proteins without affecting cell viability. These findings suggest that DMF released from gellan gum hydrogels could be a potential clinical treatment for controlling chemokine expression in chronic inflammatory conditions. [Extracted from the article]

This document is a patent application for the crystalline forms and salt forms of a kinase inhibitor. The invention aims to provide stable crystalline forms of the compound, which can have advantages such as increased stability, solubility, and bioavailability. The patent application also mentions the association of the kinase inhibitor with various cancers and the need for compounds that inhibit the kinase for the treatment of these cancers. The inventors have provided specific crystalline forms and salt forms of the compound, as well as methods for treating diseases mediated by protein kinases. The patent application was filed in May 2024 and is available for further reading on the provided URL. [Extracted from the article]

A study conducted by the David Geffen School of Medicine at the University of California, Los Angeles (UCLA) examined the safety of breastfeeding infants of patients with chronic hepatitis B (CHB) who were receiving tenofovir disoproxil fumarate (TDF) therapy. The study found that the concentration of tenofovir (TFV) in breast milk was low, resulting in negligible exposure for breastfeeding infants. Based on these findings, the researchers concluded that maternal dosing of TDF appears to be safe for breastfeeding infants from a pharmacologic and toxicity standpoint. This research has been peer-reviewed and published in the Journal of Viral Hepatitis. [Extracted from the article]

A recent report from the Instituto de Investigaciones Biomedicas in Madrid, Spain, discusses the potential therapeutic efficacy of the drug dimethyl fumarate (DMF) in treating frontotemporal dementia (FTD). FTD is a neurodegenerative disease that causes behavioral, cognitive, and language impairments. The study found that DMF, an activator of the transcription factor NRF2, demonstrated neuroprotective effects in a mouse model of FTD, reducing neurodegeneration and inflammation. The researchers suggest that DMF could be a potential treatment for FTD, particularly in cases related to the TDP-43 protein. Further research is needed to explore the effectiveness of DMF in human patients. [Extracted from the article]

A recent report discusses research on Streptococcus sobrinus, a major pathogenic bacteria involved in oral caries. The study focuses on the antibacterial and antibiofilm effects of L-Carnitine-Fumarate, a compound that inhibits the formation of biofilms and the growth of Streptococcus mutans and Streptococcus sobrinus. The research found that L-Carnitine-Fumarate showed promising results in inhibiting biofilm formation and eradicating pre-existing biofilms. The compound also demonstrated inhibitory effects on the adherence and acid tolerance of the bacteria. These findings suggest that L-Carnitine-Fumarate could be a valuable compound for preventing dental caries and biofilm formation. [Extracted from the article]

A study conducted at Federal University Ceara in Fortaleza, Brazil, explores the cocrystallization of secnidazole, an antimicrobial drug, with various coformers to produce novel solid states. The researchers successfully synthesized and characterized three novel cocrystals using synchrotron single crystal analysis. They also propose the existence of pharmaceutical cocrystals among other newly identified solid forms. This research expands the range of secnidazole-based pharmaceuticals and enhances understanding of solid form formation and the role of hydrogen bonding. The study was supported by various funding organizations. [Extracted from the article]

The article reports on new data comparing the efficacy of three therapies for relapsing multiple sclerosis: diroximel fumarate (DRF), ozanimod (OZA), and interferon beta-1a (IFN). Topics discussed include comparisons of relapse rates, disability progression, and radiological outcomes among the treatments, with DRF generally showing more favorable results compared to IFN and OZA in certain areas.

Researchers at Isfahan University of Medical Sciences in Iran have conducted a study on potential treatments for multiple sclerosis (MS). The study focused on the synthesis of hybrid structures of two FDA-approved drugs, Riluzole and dimethyl fumarate (DMF), to evaluate their potential for remyelination in MS treatment. Molecular docking experiments and in vivo evaluations were conducted, and two derivatives, D4 and D6, showed promising results in reducing degeneration in the corpus callosum. The researchers concluded that these derivatives have potential as new NMDA antagonists for the treatment of MS. The study has been peer-reviewed and published in the DARU Journal of Pharmaceutical Sciences. [Extracted from the article]

A study conducted at Beth Israel Deaconess Medical Center in Boston, Massachusetts, examined the effects of switching from dimethyl fumarate (DMF) to diroximel fumarate (DRF) in patients with multiple sclerosis (MS). The researchers found that patients who switched to DRF experienced a worsening of lymphopenia, a decrease in absolute CD8+ counts, and an increased risk of opportunistic infections. The study highlights the importance of closely monitoring lymphocyte subsets when switching MS patients from DMF to DRF. This research has been peer-reviewed and published in Multiple Sclerosis and Related Disorders. [Extracted from the article]

A systematic review conducted by researchers at the University of Washington examined the adherence-concentration-efficacy relationship of emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) pre-exposure prophylaxis (PrEP) for HIV prevention in cisgender women. The review included 11 studies and found that women-specific adherence benchmarks for FTC/TDF PrEP were within the range of historical thresholds derived from healthy men and women in the United States. The evidence suggests that adequate adherence to oral FTC/TDF PrEP, with at least four doses per week, provides sufficient HIV protection in cisgender women. However, more data is needed to refine efficacy estimates for cisgender women. [Extracted from the article]

The article focuses on the impact of tenofovir disoproxil fumarate (TDF) versus tenofovir alafenamide (TAF) on duodenal enterocytes in patients with HIV. Topics include the observed differences in duodenal villi and nutrient absorption between the two drugs, the association of TDF with higher intestinal fatty acid-binding protein (I-FABP) levels indicating enterocyte damage, and the potential explanation for TDF's effect on body weight and plasma lipids.

The article focuses on a post-hoc analysis from Nara Medical University examining the benefits of triple therapy with budesonide/glycopyrronium/formoterol fumarate dihydrate (BGF) on lung function and exacerbations in patients with COPD without an asthma diagnosis. Topics include the comparison of BGF with dual therapies based on blood eosinophil count, lung function improvements in various COPD severities, and reductions in exacerbation rates among specific patient subgroups.

A recent study conducted by researchers at Korea University in Seoul, South Korea, has found that dimethyl fumarate, a therapeutic agent known for its anti-inflammatory properties, may have potential as a treatment for endometriosis. The study showed that dimethyl fumarate had significant effects on cellular mechanisms and inhibited the growth of endometriosis lesions in a mouse model. It also regulated the immune system and reduced the expression of inflammatory cytokines. These findings suggest that dimethyl fumarate could be a promising therapeutic agent for controlling the excessive inflammatory environment associated with endometriosis. [Extracted from the article]

A study conducted by Beijing Technology and Business University in China has found that iron deficiency in infants and young children can lead to serious health issues. The researchers investigated the potential use of ferrous gluconate as an iron source in high-iron rice flour, which is commonly used as a supplementary food for infants and young children. The study found that ferrous gluconate had a higher iron absorption rate compared to ferrous fumarate in the rice flour system, particularly in a low phytic acid environment. The researchers concluded that ferrous gluconate could be a viable alternative source of iron in infant and child foods. [Extracted from the article]

A recent study conducted by researchers at the Slovak Academy of Sciences investigated the effects of chronic crowding-induced social stress and dimethyl fumarate (DMF) on borderline hypertensive rats. The study found that chronic stress increased blood pressure and the expression of the Nfe2l2 gene, as well as vasoconstriction. However, DMF treatment prevented stress-induced hypertension and mitigated vasoconstriction without affecting relaxation functions. It was also observed that DMF may produce reductive stress in the heart and induce inflammation when combined with stress. These findings suggest that DMF could be a potential treatment for chronic stress-induced hypertension, but long-term treatment should be carefully considered due to its impact on the heart. [Extracted from the article]

The article offers information on the impact of dimethyl fumarate (DMF) on subclinical biomarkers in patients with relapsing-remitting multiple sclerosis (RRMS). Topics discussed include the assessment of brain atrophy and lesion count using magnetic resonance imaging (MRI); the annualized percent brain volume change over three years of DMF treatment; and the consistency of these real-world results with previous clinical trial findings.

A report from Seattle Children's Research Institute discusses the impact of drug resistance mutations on the efficacy of antiretroviral therapy (ART) for HIV/AIDS. The study found that resistance mutations to nonnucleoside reverse transcriptase inhibitors (NNRTI) did not increase the risk of virologic failure during ART with efavirenz/tenofovir disoproxil fumarate/lamivudine. However, resistance to nucleos(t)ide reverse transcriptase inhibitors (NRTI) and NNRTI was associated with an increased risk of virologic failure. The research concludes that efavirenz-based ART can be an effective alternative to dolutegravir-based ART. [Extracted from the article]

A study conducted by researchers at the University of Barcelona examined the effects of a specific antiretroviral drug regimen on individuals with asymptomatic HIV infection. The study found that the treatment led to significant metabolic alterations, including increased levels of glucose, cholesterol, triglycerides, and hepatic enzymes, as well as decreased levels of bilirubin. However, the treatment also showed antiviral and anti-inflammatory properties, which may partially improve mitochondrial function. The findings suggest that while the regimen may cause subclinical metabolic changes, it could still be beneficial for individuals with HIV. [Extracted from the article]

A recent study conducted by researchers at the University of Texas Southwestern Medical Center explored the effects of dimethyl fumarate (DMF) on patients with radiologically isolated syndrome (RIS), a condition associated with central nervous system demyelination. The study found that DMF treatment delayed the onset of clinical events and reduced the number of new lesions in RIS patients. However, there were no significant differences in whole brain, thalamic, or subcortical gray matter volumes between treated and untreated patients. The study suggests that DMF may have a beneficial effect on CNS structures impacted by neurodegeneration. [Extracted from the article]

A study conducted at Shiraz University of Medical Sciences in Iran has explored the potential of using dimethyl fumarate (DMF) to enhance the therapeutic effects of bone marrow-derived mesenchymal stem cells (BM-MSCs) in treating neurological disorders. The researchers confirmed the identity of the stem cells and their ability to differentiate into bone and fat cells. After subjecting the stem cells to different concentrations of DMF, they found that preconditioning with DMF increased the expression of certain neurotrophic factors. The study suggests that combining BM-MSCs and DMF may have synergistic neuroprotective properties. [Extracted from the article]

Researchers at Qinghai University in Xining, China have conducted a study on the drug Albendazole (ABZ), which is used as an antiparasitic medication. The researchers focused on improving the drug's solubility, stability, and bioavailability through the creation of synthetic salts. They used various analytical techniques to characterize the properties of these salts and found that they significantly improved the solubility and dissolution rate of ABZ. The study also demonstrated that the new solid form of ABZ exhibited physical stability under adverse conditions. The researchers concluded that these findings could lead to the development of more effective and innovative drug formulations. [Extracted from the article]

A clinical trial, NCT06513312, is being conducted to study the drug lenacapavir (LEN) for HIV pre-exposure prophylaxis (PrEP). The trial aims to compare the use of LEN with the current standard treatment, emtricitabine/tenofovir disoproxil fumarate (coformulated; Truvada) (F/TDF), in individuals who would benefit from PrEP. The study will evaluate the safety, acceptability, and effectiveness of LEN and F/TDF in preventing HIV acquisition. Participants will include individuals at an increased risk of HIV, such as men who have sex with men, transgender individuals, and individuals engaged in sex work. The document provides administrative information about the study, including the study ID number and contact information for the study sponsor. [Extracted from the article]

A patent application titled "Salts And Polymorphs Of Mitragynine And 3-Deuteromitragynine" has been published by the US Patent and Trademark Office. The application, filed by Andrew Kruegel and assigned to Kures Inc., discusses the need for alternative salts and crystalline forms of mitragynine and 3-deuteromitragynine, compounds derived from the Southeast Asian plant Mitragyna speciosa. These compounds have potential therapeutic properties for pain treatment and opioid addiction. The application provides details of various salts and their characteristics, as well as pharmaceutical compositions and methods of treatment using these salts. This information may be valuable for researchers exploring the potential therapeutic uses of these compounds in treating pain, mood disorders, anxiety disorders, substance use disorders, and withdrawal symptoms. [Extracted from the article]

A patent application titled "Methods Of Administering Monomethyl Fumarate And Prodrugs Thereof Having Reduced Side Effects" has been published online. The application discusses the use of fumaric acid derivatives, such as monomethyl fumarate (MMF), for the treatment of various diseases and conditions involving immunological, autoimmune, and/or inflammatory processes. The methods described in the application aim to improve patient safety by testing for a deficiency in tissue glutathione S-transferase theta 1 enzyme (GSTT1) levels and adjusting the administration of MMF or its prodrugs accordingly. The application specifically mentions the treatment of multiple sclerosis and psoriasis as potential applications for these methods. [Extracted from the article]

The document provides information about a clinical trial investigating the effectiveness of the drug dimethyl fumarate in treating motor problems in adults with Adrenomyeloneuropathy (AMN). The trial aims to assess the safety of the drug and explore the molecular mechanisms underlying the disease. Participants will be randomly assigned to receive either dimethyl fumarate or a placebo for 36 months, with some participants switching to the active treatment after 24 months. The study is currently recruiting participants in Spain, with a target enrollment of 40 individuals, and is led by Principal Investigator Carlos Casasnovas. [Extracted from the article]

A recent preprint abstract discusses the potential benefits of dimethyl fumarate (DMF) as a treatment for Duchenne muscular dystrophy (DMD). The study found that moderate-term treatment with DMF had similar anti-inflammatory and anti-fibrotic effects on muscle as the commonly used corticosteroid, prednisone. However, DMF did not reduce muscle degeneration itself. This research suggests that DMF could be a repurposing candidate for DMD, particularly for patients who cannot tolerate long-term corticosteroid treatment. It is important to note that this preprint has not yet undergone peer review. [Extracted from the article]

A recent study conducted by researchers at Aristotle University of Thessaloniki in Greece has found that dimethyl fumarate (DMF) may improve the neuromuscular strength of mice with amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disorder. While DMF did not extend the life expectancy of the mice, it did increase the expression of Nqo1, indicating activation of the Nrf2 pathway, and decreased motor neuron degeneration. The study suggests that further clinical evaluation of DMF for the treatment of ALS is warranted. This research was funded by the Hellenic Foundation for Research and Innovation and the General Secretariat for Research and Innovation. [Extracted from the article]

A recent report from Sichuan University in Chengdu, China, focuses on fumarate hydratase-deficient renal cell carcinoma (FH-deficient RCC), a rare and highly lethal form of kidney cancer. The researchers conducted a comprehensive genomic study using tissue samples from 126 treatment-naive FH-deficient RCC patients. They found that FH alteration patterns were associated with tumor behavior and patient survival outcomes. Additionally, the study identified three molecular subtypes of FH-deficient RCC, each with different responses to treatment. These findings provide valuable insights into the aggressive nature of FH-deficient RCC and potential precision medicine approaches for disease management. [Extracted from the article]

A recent report from the University of Leuven in Belgium provides new insights into the transfer of medication through breastfeeding and its safety for nursing infants. The report focuses on the transfer of monomethyl fumarate (MMF), the active metabolite of dimethyl fumarate (DMF), in a case study involving a 32-year-old woman with multiple sclerosis. The study found a wide range of MMF concentrations in human milk samples, with estimated daily infant dosage values ranging from 5.76 to 7.68 mg/kg/day. The researchers concluded that while infant exposure to MMF is low, further research is needed to assess its safety. [Extracted from the article]

A recent study conducted by Biogen Inc. evaluated the safety, tolerability, and efficacy of diroximel fumarate (DRF) in patients with relapsing-remitting multiple sclerosis (MS). The study used a composite efficacy endpoint called No Evidence of Disease Activity (NEDA-3), which includes criteria such as no relapse, no disability progression, and no new lesions. The results showed that approximately half of the DRF-treated patients achieved NEDA-3 at week 96 after re-baselining, compared to 36.5% of patients who were not re-baselined. Re-baselining may be a useful approach to assess the efficacy of disease-modifying therapies for MS. [Extracted from the article]

A recent study conducted by researchers at Tulane University School of Medicine in New Orleans has found that dimethyl fumarate (DMF), a medication used to treat multiple sclerosis, may have negative effects on vascular smooth muscle cells (VSMCs) in the context of cerebral aneurysm. The study used single-cell RNA-sequencing to analyze the impact of DMF on VSMCs and found that DMF treatment impaired the transcription of certain genes involved in antioxidant functions and mitochondrial respiration in VSMCs. This led to vulnerability to oxidative stress, mitochondrial dysfunction, and enhanced apoptosis. The researchers suggest that monitoring patients undergoing DMF treatment for biomarkers linked to these effects may be clinically relevant. [Extracted from the article]

A recent study conducted by researchers at University College London (UCL) has found that dimethyl fumarate (DMF) may have potential as a novel therapy for systemic lupus erythematosus (SLE). The study investigated the effects of DMF on T cell metabolism and function in SLE patient samples. The results showed that DMF inhibited T cell activation, proliferation, and the expression of activating NK receptors, as well as reducing the secretion of proinflammatory cytokines. These findings suggest that DMF could be a promising treatment option for SLE, and further research is warranted. [Extracted from the article]

Researchers from the Shengli Clinical Medical College of Fujian Medical University in China have conducted a study on the therapeutic efficacy of dimethyl fumarate (DMF) in treating acute kidney injury (AKI) after traumatic brain injury (TBI). The study found that AKI frequently occurs as a non-neurological consequence of TBI and contributes to increased mortality risks. The researchers discovered that DMF effectively alleviated oxidative stress-induced AKI by activating the Keap1-Nrf2/HO-1 signaling pathway, suggesting that this pathway could be a potential therapeutic strategy for attenuating AKI after TBI. This research provides valuable insights into the treatment of AKI in TBI patients. [Extracted from the article]

A recent research study conducted by the Icahn School of Medicine at Mount Sinai in New York has found that the use of tenofovir disoproxil fumarate (TDF) in pregnant women living with HIV can lead to decreased bone mineral content in their HIV-exposed uninfected (HEU) neonates. The study analyzed blood and urine samples from neonates exposed to TDF in utero and found that they had increased urinary loss of phosphate and lower serum concentrations of 25(OH)D. The potential mechanisms behind these findings are still unknown. This research provides valuable insights into the effects of TDF on neonatal health and highlights the need for further investigation in this area. [Extracted from the article]

A recent report from the Ottawa Hospital Research Institute in Canada discusses the potential of tepilamide fumarate (TPF) in enhancing the effectiveness of oncolytic virotherapy, a treatment that uses viruses to selectively attack cancer cells. The study found that TPF increased viral replication and improved the killing of resistant cancer cells in vitro. Ex vivo studies also showed that TPF selectively boosted oncolytic virus infection in cancer cells without affecting healthy tissues, particularly in pancreatic and ovarian tumor samples. The research suggests that TPF has potential not only in oncolytic virotherapy but also in gene therapy, warranting further exploration of its therapeutic potential. [Extracted from the article]